文献速递心境障碍精神分裂症与精神病性障碍老年精神

纳米颗粒治疗精神与神经疾病的临床创新与未来方向

Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders.
PubMed 文献 · Mol Psychiatry · 2026-04-14

本综述指出纳米颗粒(NPs)凭借可调尺寸、表面化学与载荷控制,可跨越血脑屏障、靶向特定细胞并实现缓释或刺激响应释放,在抑郁、精神分裂症、阿尔茨海默病与帕金森病的临床前研究中显示优于游离药物的暴露、靶点结合及行为或认知获益;但临床转化尚早,仅少数中枢神经系统(CNS)候选药物在试验中,批准多不在CNS适应症。

要点

  • 脂质、聚合物、无机及杂化NPs可经受体/转运体途径穿越血脑屏障并靶向递送。
  • 临床前抑郁、精神分裂症、阿尔茨海默病与帕金森病研究显示NPs优于游离药物。
  • 临床转化早期,障碍包括血脑屏障完整性变异、免疫原性与蛋白冠效应等。

核心结论

  • 纳米颗粒在精神与神经疾病中具备跨越血脑屏障、靶向递送与改善成像/基因治疗等潜力,但临床转化尚处早期。

研究设计与样本

  • 本综述汇总脂质、聚合物、无机及杂化纳米颗粒在精神与神经疾病中的临床前与临床转化研究。

主要发现

  • 临床前研究显示NPs在抑郁、精神分裂症、阿尔茨海默病与帕金森病中较游离药物有更优暴露、靶点结合及行为或认知获益。
  • 临床仅有少数CNS导向候选药物(如金基生物能量剂、鼻内脂质制剂、脂质体调节剂)在试验中,批准多不在CNS适应症。
  • NPs还可改善成像、实现基因/RNA治疗并支持抗炎与神经保护策略。

关键数值与推荐

  • 临床前研究显示NPs较游离药物在抑郁、精神分裂症、阿尔茨海默病与帕金森病中具有更优暴露、靶点结合及行为或认知获益。
  • 临床转化障碍包括血脑屏障完整性变异、免疫原性与蛋白冠效应、生产与稳定性限制及人体效应部位暴露-反应数据有限。

临床怎么用

  • 推荐采用模型引导开发,将制剂与脑间质暴露关联,并采用质量源于设计(QbD)的化学、制造与控制(CMC)。
  • 建议开展分层、适应性试验,整合群体药代动力学/药效学(PK/PD)与统一生物标志物,并主动进行长期注册安全监测。
  • 可探索靶向肠-脑轴的NPs策略(递送益生菌、代谢物或抗菌药)作为调节神经炎症与回路功能的补充途径。

局限性

  • 临床转化尚早,人体效应部位暴露-反应数据有限,批准多不在CNS适应症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nanoparticles (NPs) provide a versatile toolkit for psychiatry and neurology by leveraging tunable size, surface chemistry, and payload control to overcome long-standing barriers in central nervous system (CNS) therapy. Lipid, polymeric, inorganic, and hybrid NPs can be engineered to traverse the blood-brain barrier (BBB) via receptor/transporter pathways, target specific cell types, and deliver sustained or stimuli-responsive release. Beyond drug delivery, NPs improve imaging, enable gene/RNA therapeutics, and support anti-inflammatory and neuroprotective strategies, advancing precision medicine. Preclinical studies in depression, schizophrenia, Alzheimer's disease, and Parkinson's disease show superior exposure, target engagement, and behavioral or cognitive benefits versus free drugs, including photothermal/photodynamic and nanobody-based approaches. Clinically, translation remains early: a handful of CNS-directed candidates (e.g., gold-based bioenergetic agents, intranasal lipid formulations, liposomal modulators) are in trials, while approvals largely lie outside CNS indications. Key hurdles include variable BBB integrity, immunogenicity and protein-corona effects, manufacturing and stability constraints, and limited effect-site exposure-response data in humans. This review outlines a translational playbook: model-informed development linking formulation to brain interstitial exposure; Quality-by-Design chemistry, manufacturing, and controls (CMC); stratified, adaptive trials with population PK/PD and harmonized biomarkers; and proactive safety monitoring with long-term registries. We also highlight NP strategies targeting the gut-brain axis-delivering probiotics, metabolites, or antimicrobials-as complementary routes to modulate neuroinflammation and circuit function. With rigorous clinical science, manufacturing quality, and safety governance embedded from the outset, nanotechnology is positioned to deliver safer, more effective, and potentially disease-modifying therapies for CNS disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Zhu TT, Liu PM, Hashimoto K, et al. Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders. Mol Psychiatry. 2026. PMID: 41981211. doi:10.1038/s41380-026-03603-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。